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hronic myeloid leukemia (CML) is a hematological malig-
ancy in which a high percentage of patients cytogenetically
xpress the Philadelphia chromosome. This chromosome
esults from the reciprocal translocation, t(9;22)(q34;q11.2).
uring this exchange, the Abelson gene (abl) on chromosome
 and the breakpoint cluster region gene (bcr) on chromosome
2 generate the breakpoint cluster region-Abelson murine
eukemia (BCR-ABL) fusion gene. The most frequent break-
oint on chromosome 22, located between exons 12 and 16,
s called the major breakpoint cluster region (M-bcr) and with
ts counterpart in exon 2 of chromosome 9 results in the b2a2
nd b3a2 transcripts that code for a 210 kDa protein. Less fre-
uently, a second rearrangement, minor breakpoint cluster
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eserved.region (m-bcr), occurs between the ﬁrst intron of the bcr gene
and exon 2 of the abl gene producing the e1a2 transcript that
codes for a 190 kDa protein.1–4 This fusion transcript occurs
in 1–2% of CML patients as a sole rearrangement with the
ﬁrst three cases being described in 1990.5–7 These patients
may have a particular clinical condition between CML  and
chronic myelomonocytic leukemia (CMML). The third type of
transcript is e19a2 which occurs between exons 19 and 20 of
the bcr gene and exon 2 of the abl gene. This is called the micro
breakpoint cluster region (-bcr) coding for a 230 kDa protein.
Among other unusual transcripts are e6a2, e2a2, e1a3, b2a3
and b3a3.1,2 The objective of this article is to describe a casespital Privado - Centro Médico de Córdoba, Naciones Unidas 346,
of CML with a minor p190 molecular rearrangement causing
monocytosis in peripheral blood, dysplastic changes in the
bone marrow and lack of response to treatment with tyrosine
kinase inhibitors.
 e Terapia Celular. Published by Elsevier Editora Ltda. All rights
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Case  report
A 65-year-old female had a history of type 2 diabetes mel-
litus, and a diagnosis of CML  made in August 2011 at
another institution. At the time of diagnosis, the patient pre-
sented splenomegaly, with a white blood cell count (WBC)
of 380 × 109/L, hemoglobin (Hb) level of 8.8 g/dL and platelet
count of 560 × 109/L. The bone marrow aspirate showed
marked granulocytic hyperplasia and a cytogenetic test of 20
metaphases exhibited a t(9;22)(q34;q11) in the entire sample.
At that time, neither molecular biology analyses nor ﬂuo-
rescent in situ hybridization (FISH) was performed. Therapy
with hydroxyurea was prescribed, and in September 2011 the
administration of imatinib (400 mg/day) was begun. In October
2011, the red blood count was normal, the WBC  was 7.3 × 109/L,
Hb was 9.2 g/dL and platelet count was 230 × 109/L; at this
time, the patient reported hair loss and edema. In Novem-
ber 2011, imatinib therapy was stopped due to pancytopenia
(WBC: 2 × 109/L). In December 2011, the patient was referred
to our hospital: she was under no treatment and presented
mild splenomegaly. In January 2012, her WBC  was 11.9 × 109/L
with monocytosis (49% neutrophils, 2% basophils, 28% lym-
phocytes and 21% monocytes), Hb level was 11.57 g/dL and
platelet count was 192 × 109/L. A bone marrow aspirate was
performed. It revealed marked bone marrow hyperplasia, and
dysplastic changes in the myeloid as well as in the erythroid
series.
Cytogenetics showed 46,XX, t(9;22)(q34;q11) in 20
metaphases, and the FISH analysis conﬁrmed the BCR-ABL
fusion in 100% of the sample. A nested reverse transcription
polymerase chain reaction (RT-PCR)4 of the bone marrow
was positive for the m-bcr rearrangement with a 381 base
pair (bp) product in the sample obtained in January 2012. No
bands for the M-bcr rearrangement were found. The material
from the patient and the control sample were high quality
according to the ampliﬁcation product of the 300 bp abl gene.
This result was conﬁrmed by sequence analysis. A RT-PCR
was performed in order to quantify the number of copies
of the m-bcr BCR-ABL transcript. A set of primers and a
TaqMan probe (Applied Biosystems) were used for the e1a2
transcript and for the abl control gene; negative controls were
also included in the assays.8 Nanogen molecular standards
(Nanogen Advanced Diagnostics S.p.A., Corso Torino, Italy)
were employed for the calibration curve. The assays were
carried out in an Applied 7500 real time PCR system (Applied
Biosystems Life). The BCR-ABL and ABL transcripts were
analyzed in duplicate, and the number of BCR-ABL transcripts
was normalized by the expression of ABL. The copy number
variation of the e1a2 transcript in the patient’s sample was
94.4%.
The patient restarted imatinib (400 mg/day). Three months
later, a bone marrow aspirate showed bone marrow hyperpla-
sia with mild megaloblastic changes and absence of response
according to cytogenetics and FISH. The copy number vari-
ation of the e1a2 transcript by RQ-PCR was 76.1%. These
samples were analyzed to detect if the patient presented
mutations in the ABL kinase domain; all were negative.
The administration of imatinib was increased to
800 mg/day without achieving response. In June 2012,r. 2 0 1 5;3 7(1):55–57
imatinib was replaced by dasatinib (100 mg/day) due to the
lack of response. Three months later, a new evaluation of the
patient revealed a better cytogenetic response. However, after
a year of treatment the results of a FISH analysis showed a
positive BCR-ABL fusion gene in 85% of the sample. Thus, the
treatment was changed to nilotinib 400 mg/12 h. Under this
medication, which is ongoing, the pancytopenia persists.
Discussion
The case described was referred to our institution with a diag-
nosis of CML and under no treatment due to pancytopenia. On
admission, the patient’s bone marrow was reexamined and
the cytogenetic analysis showed Philadelphia chromosomes
in all of the metaphases analyzed; this result was conﬁrmed
by FISH, which revealed a BCR-ABL fusion gene in 100% of the
sample, and by RT-PCR, which identiﬁed an m-bcr BCR-ABL
mutation with an e1a2 transcript that encodes for a 190 kDa
protein. Subsequently, the transcript was quantiﬁed by RQ-
PCR and a BCR-ABL/ABL ratio of 94.4% was obtained. At the
time of diagnosis, most CML patients have an M-bcr BCR-ABL
molecular rearrangement corresponding to the b2a2 or b3a2
transcripts. In a large series of patients with CML, the fre-
quency of the m-bcr e1a2 p190 molecular rearrangement was
1–2%.9,10 The coexistence of M-bcr and m-bcr rearrangements,
apparently due to alternative splicing, has also been described.
The red blood count performed at our institution revealed
absolute and relative monocytosis with granulocytic hyper-
plasia and dysplasia of the bone marrow. Several authors
report BCR-ABL p190 CML cases with monocytosis, sharing
some features with myelodysplastic/myeloproliferative neo-
plasms (MDS/MPN) due to the differentiation of both lineages,
granulocytes and monocytes. Even though the unique feature
of the BCR-ABL p190 CML  seems to be monocytosis without
splenomegaly,11,12 this entity can also present without mono-
cytosis, with basophilia or with splenomegaly. It seems that
there is no characteristic pattern in these cases; it can only be
conﬁrmed that some patients present monocytosis at diagno-
sis or during the course of the disease, and others, with or
without splenomegaly, have no monocytosis. In the current
case it is not exactly known if the patient had monocytosis
at the time of diagnosis or not, but she did present with this
feature when she was admitted to our institution.
The prognosis of patients with the BCR-ABL p190 molecu-
lar rearrangement in CML  is controversial. There are doubts
as to whether this rearrangement has a poor prognosis
independent of the therapy used,9,10 or whether patients
are candidates for bone marrow transplantation in the
case of advanced disease. Twenty-three articles reporting
on p190 CML cases were found in the literature with some
authors proposing bone marrow transplant in cases of dis-
ease progression.9 The patient herein reported had a rapid
response to dasatinib therapy, but according to FISH analy-
sis, after a year of treatment she again presented a positive
BCR-ABL fusion gene, which resulted in a change of treatment
due to the lack of response. Although the follow-up in this
case is short, it can be seen that the BCR-ABL p190 molecular
rearrangement is difﬁcult to treat as has already been reported
in the literature.
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BCR-ABL p190 CML  may have unique clinical and biological
eatures. Identifying these patients at the time of diagnosis
ould allow the optimization of treatment.
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